Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years

Authors: Mounia Elidrissi Errahhali, Manal Elidrissi Errahhali, Redouane Boulouiz, Meryem Ouarzane, Mohammed Bellaoui

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Hematological malignancies (HM) are a public health problem. The pattern and distribution of diagnosed hematological cancers vary depending on age, sex, geography, and ethnicity suggesting the involvement of genetic and environmental factors for the development of these diseases. To our knowledge, there is no published report on HM in the case of Eastern Morocco. In this report we present for the first time the overall pattern of HM for this region.

Methods

Retrospective descriptive study of patients diagnosed with HM between January 2008 and December 2012 in three centres in Eastern Morocco providing cancer diagnosis, treatment or palliative care services. The FAB (French-American-British) classification system has been taken into account in the analysis of myeloid and lymphoid neoplasms.

Results

In this study, a total of 660 cases of HM were registered between January 2008 and December 2012. Overall, 6075 cases of cancers all sites combined were registered during this study period, indicating that HM account for around 10.9 % (660/6075) of all cancers recorded. Among the 660 registered cases of HM, 53 % were males and 47 % were females, with a male to female ratio of 1.1. Thus, overall, men are slightly more affected with HM than women. By contrast, a female predominance was observed in the case of Hodgkin’s lymphoma (HL), myeloproliferative neoplasms (MPN), acute myeloid leukemia (AML) and the myelodysplastic syndrome (MDS). HM occur at a relatively young age, with an overall median age at diagnosis of 54 years. Non-Hodgkin’s lymphoma (NHL) was the most common HM accounting for 29.7 % of all HM, followed by HL, MPN, multiple myelomas (MM), chronic lymphocytic leukemia (CLL), AML, MDS, acute lymphoblastic leukemia (ALL), and Waldenström macroglobulinemia (WM). The majority of HM cases have been observed among patients aged 60 years and over (40.4 % of HM). Among this age group, NHL was the most common HM. In adolescents, HL was the most frequent HM.

Conclusions

This study provided for the first time the pattern and distribution of HM in Eastern Morocco. Our findings justify the need to establish a regional cancer registry as a first step in blood cancer control in Eastern Morocco.
Appendix
Available only for authorised users
Literature
1.
Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer. 2007;31(3):182–201.CrossRefPubMed
2.
Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–7.PubMed
3.
Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, World Health Organization Classification of tumours. Lyon, France: Iarc Presse; 2001.
4.
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–302.CrossRefPubMed
5.
Swerdllow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. France: IARC Press; 2008.
6.
Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.CrossRefPubMed
7.
Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–32.PubMedCentralCrossRefPubMed
8.
Gupta G, Singh R, Kotasthane DS, Kotasthane VD. Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors–international Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues. J Blood Med. 2010;1:171.PubMedCentralCrossRefPubMed
9.
Hasserjian RP, Ott G, Elenitoba-Johnson KS, Balague-Ponz O, de Jong D, de Leval L. Commentary on the WHO classification of tumors of lymphoid tissues (2008):“Gray zone” lymphomas overlapping with Burkitt lymphoma or classical Hodgkin lymphoma. J Hematop. 2009;2(2):89–95.PubMedCentralCrossRefPubMed
10.
Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood. 2010;116(20):e90.PubMedCentralCrossRefPubMed
11.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed
12.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136(5):E359–86.CrossRefPubMed
13.
Bouchbika Z, Haddad H, Benchakroun N, Kotbi S, Megrini A, Bourezgui H, et al. Cancer incidence in Morocco: report from Casablanca registry 2005-2007. Pan Afr Med J. 2013;16(1):31.PubMedCentralPubMed
14.
Sahraoui S, Benider A, Bennani O, Karkouri M, Ennaji H, Kotb S, et al. Incidence cancer in Casablanca region in 2004: First results from the greater Casablanca cancer registry (GCCR). Int Res J. 2013;1(3):35–45.
15.
16.
HCP: Monograph of the region of Eastern Morocco 2012 (In French). Oujda Regional Directorate; 2012.
17.
18.
Leclair SJ, Rodak BF. The new WHO nomenclature: lymphoid neoplasms. Clin Lab Sci. 2002;15(1):55–9.PubMed
19.
Rodak BF, Leclair SJ. The new WHO nomenclature: Introduction and myeloid meoplasms. Clin Lab Sci. 2002;15(1):44–54.PubMed
20.
RECRAB. Cancer registry Rabat, 2005 (French). 2009.
21.
22.
23.
Babatunde A, Amiwero C, Olatunji P, Durotoye I. Pattern of haematological malignancies in Ilorin, Nigeria: a ten year review. Internet J Hematol 2009, 5(2).
24.
Mashhadi M, Zakeri Z, Abdollahinejad M. Cancer incidence in South East of Iran: results of a population-based cancer registry. Shiraz E Med J. 2010;11(3):148–55.
25.
Ba Saleem HO, Bawazir AA, Moore M, Abdulla K. Five years cancer incidence in Aden Cancer Registry, Yemen. Asian Pac J Cancer Prev. 2010;11:507–11.PubMed
26.
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. Cancer incidence in five continents, vol. 9. International Agency for Research on Cancer; 2007.
27.
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–34.CrossRefPubMed
28.
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684–92.PubMedCentralCrossRefPubMed
29.
Thiam D, Diop S, Diop T, Tallarmin F, Toure A, Diakhate L. Epidemiology and therapy of malignant hemopathies in Senega. Hematol Cell Ther. 1996;38(2):187–91.CrossRefPubMed
30.
Troussard X, Duchenet V, Cornet E, Mouchel D, Malet M, Collignon A. Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004. Rev Epidemiol Sante Publique. 2009;57(3):151–8.CrossRefPubMed
31.
Hossain MS, Iqbal MS, Khan MA, Rabbani MG, Khatun H, Munira S, et al. Diagnosed hematological malignancies in Bangladesh-a retrospective analysis of over 5000 cases from 10 specialized hospitals. BMC Cancer. 2014;14(1):438.PubMedCentralCrossRefPubMed
32.
Pearce MS, Parker L. Childhood cancer registrations in the developing world: still more boys than girls. Int J Cancer. 2001;91(3):402–6.CrossRefPubMed
33.
Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118(4):1071–7.CrossRefPubMed
34.
35.
36.
Ho C, Butera JN. Acute myeloid leukemia in the elderly, vol. 94. Rhode Island: Medicine and Health; 2011.
37.
Peyrade F, Gastaud L, Ré D, Pacquelet-Cheli S, Thyss A. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncology. 2012;13(8):e344–52.CrossRefPubMed
38.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.CrossRefPubMed
39.
Kruger M, Hendricks M, Davidson A, Stefan CD, van Eyssen AL, Uys R, et al. Childhood cancer in Africa. Pediatr Blood Cancer. 2014;61(4):587–92.CrossRefPubMed
40.
41.
Hadley LG, Rouma BS, Saad-Eldin Y. Challenge of pediatric oncology in Africa. Semin Pediatr Surg. 2012;21(2):136–41.CrossRefPubMed
42.
Stiller CA. International patterns of cancer incidence in adolescents. Cancer Treat Rev. 2007;33(7):631–45.CrossRefPubMed
43.
Arora R, Eden T, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer. 2009;46(4):264.CrossRefPubMed
44.
Grömminger S, Mautner J, Bornkamm GW. Burkitt lymphoma: the role of Epstein-Barr virus revisited. Br J Haematol. 2012;156(6):719–29.CrossRefPubMed
45.
46.
Vedham V, Divi RL, Starks VL, Verma M. Multiple Infections and Cancer: Implications in Epidemiology. Technol Cancer Res Treat. 2013;13(2):177–94.PubMed
47.
Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, et al. The Epstein–Barr virus and the pathogenesis of lymphoma. J Pathol. 2015;235(2):312–22.CrossRefPubMed
48.
Lightfoot TJ, Roman E. Causes of childhood leukaemia and lymphoma. Toxicol Appl Pharmacol. 2004;199(2):104–17.CrossRefPubMed
49.
Rudant J, Menegaux F, Leverger G, Baruchel A, Lambilliotte A, Bertrand Y, et al. Childhood hematopoietic malignancies and parental use of tobacco and alcohol: the ESCALE study (SFCE). Cancer Causes Control. 2008;19(10):1277–90.CrossRefPubMed
50.
Saberi Hosnijeh F, Peeters P, Romieu I, Kelly R, Riboli E, Olsen A, et al. Dietary intakes and risk of lymphoid and myeloid leukemia in the European Prospective Investigation into Cancer and Nutrition (EPIC). Nutr Cancer. 2014;66(1):14–28.CrossRefPubMed
51.
Amégbor K, Darré T, Padaro E, Pegbessou E, Bagny A, Napo-Koura G. Epidemiology and pathological profile of lymphomas in Togo: about 755 cases observed in the Tokoin hospital of Lomé. Afr J Cancer. 2010;2(4):235–9.CrossRef
52.
Omoti CE, Nwannadi AI, Obieche JC, Olu-Eddo AN. The epidemiological features of lymphoid malignancies in Benin City, Nigeria: a 15 years study. Pan Afr Med J. 2012;11:10.PubMedCentralPubMed
53.
54.
Park HJ, Park EH, Jung KW, Kong HJ, Won YJ, Lee JY, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol. 2012;47(1):28–38.PubMedCentralCrossRefPubMed
55.
RCRC. Cancer Registry of the great Casablanca Region 2005-2007 (French). 2012.
56.
RCRC. Cancer Registry of the Greater Casablanca Region 2004 (French). 2004.
57.
Aoki R, Karube K, Sugita Y, Nomura Y, Shimizu K, Kimura Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int. 2008;58(3):174–82.CrossRefPubMed
58.
Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma. 2013;54(5):1004–11.CrossRefPubMed
59.
Yang Q-P, Zhang W-Y, Yu J-B, Zhao S, Xu H, Wang W-Y, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6:77.PubMedCentralCrossRefPubMed
60.
Yoon SO, Suh C, Lee DH, Chi HS, Park CJ, Jang SS, et al. Distribution of lymphoid neoplasms in the Republic of Korea: analysis of 5318 cases according to the World Health Organization classification. Am J Hematol. 2010;85(10):760–4.CrossRefPubMed
61.
Armstrong A, Alexander F, Cartwright R, Angus B, Krajewski A, Wright D, et al. Epstein-Barr virus and Hodgkin’s disease: further evidence for the three disease hypothesis. Leukemia. 1998;12(8):1272–6.CrossRefPubMed
62.
Macfarlane GJ, Evstifeeva T, Boyle P, Grufferman S. International patterns in the occurrence of Hodgkin’s disease in children and young adult males. Int J Cancer. 1995;61(2):165–9.CrossRefPubMed
63.
McNally R, Rowland D, Roman E, Cartwright R. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol. 1997;15(4):173–89.CrossRefPubMed
64.
Bhurgri Y, Bhurgri A, Hassan SH, Zaidi S, Rahim A, Sankaranarayanan R, et al. Cancer incidence in Karachi, Pakistan: first results from Karachi cancer registry. Int J Cancer. 2000;85(3):325–9.CrossRefPubMed
65.
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.CrossRefPubMed
66.
Huang SY, Yao M, Tang JL, Lee WC, Tsay W, Cheng AL, et al. Epidemiology of multiple myeloma in Taiwan. Cancer. 2007;110(4):896–905.CrossRefPubMed
67.
Kumar L, Verma R, Radhakrishnan VR. Recent advances in the management of multiple myeloma. Natl Med J India. 2010;23(4):210–8.PubMed
68.
Harousseau J, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v155–7.CrossRefPubMed
69.
Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67(3):152–7.CrossRefPubMed
70.
Gogia A, Sharma A, Raina V, Kumar L, Vishnubhatla S, Gupta R, et al. Assessment of 285 cases of chronic lymphocytic leukemia seen at single large tertiary center in Northern India. Leuk Lymphoma. 2012;53(10):1961–5.CrossRefPubMed
71.
Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol. 2007;18:i3.CrossRefPubMed
72.
Clarke CA, Glaser SL, Gomez SL, Wang SS, Keegan TH, Yang J, et al. Lymphoid malignancies in US Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1064–77.PubMedCentralCrossRefPubMed
73.
Shvidel L, Shtarlid M, Klepfish A, Sigler E, Berrebi A. Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel. Leukemia. 1998;12(10):1612–7.CrossRefPubMed
74.
Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v78–84.CrossRefPubMed
75.
Shamebo M, Gebremedhin A. Chronic lymphocytic leukaemia in Ethiopians. East Afr Med J. 1996;73(10):643–6.PubMed
76.
Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98(2):222–9.PubMedCentralCrossRefPubMed
77.
Devine SM, Larson RA. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J Clin. 1994;44(6):326–52.CrossRefPubMed
78.
Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol. 2010;148(5):739–53.PubMedCentralCrossRefPubMed
79.
Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, et al. Alcohol consumption and risk of leukemia: a multicenter case–control study. Leuk Res. 2007;31(3):379–86.CrossRefPubMed
80.
Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. Med Oncol. 2002;19(3):141–50.CrossRefPubMed
81.
Cheng Y, Wang Y, Wang H, Chen Z, Lou J, Xu H, et al. Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia. 2009;23(10):1801–6.CrossRefPubMed
82.
Abolfazl M, Fatemeh I, Hamid A, Mojtaba G, Alireza MJ, Ali MM. Specific chromosomal abnormalities in patients with acute nonlymphocytic leukemia from the Islamic Republic of Iran. Asian Pac J Cancer Prev. 2006;7(3):447–50.PubMed
83.
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T. Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. Ann Hematol. 2005;84(12):785–91.CrossRefPubMed
84.
Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325–36.CrossRefPubMed
85.
Enjeti AK, Tien SL, Sivaswaren CR. Cytogenetic abnormalities in de novo acute myeloid leukemia in adults: relation to morphology, age, sex and ethnicity - a single center study from Singapore. Hematol J. 2004;5(5):419–25.CrossRefPubMed
86.
Kadam PR, Merchant AA, Advani SH, Nair C. Specific chromosomal changes in patients with acute nonlymphocytic leukemia from India. Hematol Oncol. 1991;9(1):17–32.CrossRefPubMed
87.
Kar R, Rao S, Saxena R. Myelodysplastic syndromes: classification and prognostic scoring systems and their applicability in Indian scenario-experience from a tertiary care center. Hematology. 2009;14(3):145–9.CrossRefPubMed
Metadata
Title
Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years
Authors
Mounia Elidrissi Errahhali
Manal Elidrissi Errahhali
Redouane Boulouiz
Meryem Ouarzane
Mohammed Bellaoui
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2205-5

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis

Research article

The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer

Research article

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Research article

Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine

Research article

Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes

Research Article

Differences in predictions of ODE models of tumor growth: a cautionary example
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits